15-Year Gap Exposed: Opioid Book Reveals Biopharma’s Unchecked Marketing

For the biopharmaceutical sector, Caverson's memoir is a chilling case study in what happens when product ambition outruns safety evidence. The book documents how a drug originally designed for end-of-life care was repositioned as a general pain remedy, held aloft by aggressive promotion rather than rigorous long-term data. As companies pursue next-generation analgesics, the OxyContin legacy serves as a permanent warning: marketing claims must be matched by real-world monitoring and ethical prescribing guardrails from day one.

In the mid-1990s, a potent new painkiller — a 12-hour time-release formulation of oxycodone branded OxyContin — was approved in Canada and introduced as a revolutionary advance in chronic pain management. Marketed aggressively as less prone to abuse than its predecessors, it rapidly became the default prescription for everything from back pain to dental procedures. The consequences, as is now well-documented, were catastrophic. In her new book, Opioids: Burying the Truth One Person at a Time, Reggie Caverson, a former drug strategist with over three decades of frontline experience, reveals how she witnessed the genesis of Canada’s opioid epidemic from inside the system — and was systematically silenced when she raised the alarm.

“

She led the development of a drug strategy for Ontario, was the provincial lead on national projects addressing substance abuse with the Canadian Centre on Substance Abuse, and co-founded the Municipal Drug Strategy Coordinators Network of Ontario.

Caverson’s credentials are formidable. She led the development of a drug strategy for Ontario, was the provincial lead on national projects addressing substance abuse with the Canadian Centre on Substance Abuse, and co-founded the Municipal Drug Strategy Coordinators Network of Ontario. Drawing on that deep institutional knowledge, she argues that the opioid disaster was not an accident but the result of a deliberate regression in medical oversight, where a medication originally intended for end-of-life and cancer care was repurposed, with little evidence, into a blanket treatment for everyday pain. For 15 years — from 1996 until national prescribing guidelines were finally released around 2011 — OxyContin remained the default analgesic, untouched by regulatory scrutiny. By the time the guidelines arrived, tens of thousands of Canadians were already addicted.

The arc of Caverson’s story is particularly instructive for the biopharmaceutical industry and healthcare regulators. While working with police services across the country, she observed dramatic spikes in street crime and substance misuse that directly correlated with spikes in opioid prescribing. Her warnings to colleagues and supervisors were met with what she describes as a “wall of silence.” Ultimately, despite her experience and success in shaping Ontario’s addiction strategy, she was terminated from her position. Her narrative underscores a pernicious dynamic that pervaded the early years of the crisis: the institutional resistance to challenging the safety profile of a blockbuster pharmaceutical product, especially one that was generating enormous revenue for manufacturers and appeared to offer a humane solution to chronic pain.

The book’s title, “Burying the Truth One Person at a Time,” speaks to the human cost. While Caverson’s account is grounded in Canada, the mechanisms she describes mirror the American experience, where Purdue Pharma’s marketing machine overstated benefits and downplayed addiction risks. For biotech and pharma stakeholders, the ongoing litigation and reputational wreckage serve as a permanent warning about the perils of lax post-market surveillance and overeager commercialization. The OxyContin saga revealed fundamental cracks in the safety monitoring system: clinical trials focused narrowly on efficacy in controlled settings, with insufficient long-term data on abuse liability. Regulatory bodies, often under-resourced, relied heavily on manufacturer-supplied data without robust independent verification. Caverson’s documentation of these failures provides a blueprint for what must change: mandatory real-world evidence programs, transparent adverse event reporting, and independent oversight of marketing claims.